Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Spyre TherapeuticsFRA:3920 +2.89%26 Return-on-Tangible-Equity is -40.09% as of Mar. 2026. GuruFocus rates FRA:3920 with a GF Score™ of 26/100. The stock has 4 warning signs investors should review. Among 1,199 Biotechnology companies, Spyre Therapeutics ranks better than 55.96% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Spyre Therapeutics's annualized net income for the quarter that ended in Mar. 2026 was €-238.76 Mil. Spyre Therapeutics's average shareholder tangible equity for the quarter that ended in Mar. 2026 was €595.53 Mil. Therefore, Spyre Therapeutics's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was -40.09%.
The historical rank and industry rank for Spyre Therapeutics's Return-on-Tangible-Equity or its related term are showing as below:
FRA:3920'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -289.17 Med: -67.3 Max: -25.17
Current: -32.28
During the past 13 years, Spyre Therapeutics's highest Return-on-Tangible-Equity was -25.17%. The lowest was -289.17%. And the median was -67.30%.
FRA:3920's Return-on-Tangible-Equity is ranked better than 55.96% of 1199
companies
in the Biotechnology industry
Industry Median: -42.4
vs FRA:3920: -32.28
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Spyre Therapeutics Return-on-Tangible-Equity Related Terms
Spyre Therapeutics Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Spyre Therapeutics's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:3920 vs MIRM, RYTM, PTGX: Return-on-Tangible-Equity Comparison
For the Biotechnology subindustry, Spyre Therapeutics's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Spyre Therapeutics Return-on-Tangible-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Spyre Therapeutics's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Spyre Therapeutics's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of -40.09% mean?
Spyre Therapeutics (FRA:3920) has a Return-on-Tangible-Equity of -40.09% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Spyre Therapeutics and its competitors. According to the industry distribution chart, Spyre Therapeutics ranks #528 out of 1199 companies in the Biotechnology industry, placing it in the top 44%.
Is Spyre Therapeutics' Return-on-Tangible-Equity too high?
Spyre Therapeutics' current Return-on-Tangible-Equity is -40.09%. Based on the distribution chart, Spyre Therapeutics ranks #528 out of 1199 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Spyre Therapeutics has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Spyre Therapeutics' Return-on-Tangible-Equity compare to MIRM and RYTM?
According to the Biotechnology industry distribution chart, Spyre Therapeutics ranks #528 out of 1199 companies for Return-on-Tangible-Equity. This puts Spyre Therapeutics in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Biotechnology company?
A good Return-on-Tangible-Equity depends on the Biotechnology industry context. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Spyre Therapeutics and its competitors. Spyre Therapeutics's current Return-on-Tangible-Equity is -40.09%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Spyre Therapeutics stock overvalued right now?
Spyre Therapeutics (FRA:3920) has a current Return-on-Tangible-Equity of -40.09%. The current Return-on-Tangible-Equity is -40.09%. Spyre Therapeutics' overall GF Score™ is 26/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Spyre Therapeutics (FRA:3920), the current Return-on-Tangible-Equity is -40.09% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Spyre Therapeutics Inc is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (IBD) and rheumatic diseases. Spyre's pipeline includes extended half-life antibodies targeting ?4?7, TL1A, and IL-23 in development as monotherapies and pair-wise combinations. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.
26GF Score
Get the complete analysis for FRA:3920
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:3920 has been successfully added to your 
